35009-16-6

Upstream product

• 34040-64-7 p-methyloxycarbonylbenzyl chloride 
• 333-20-0 potassium thioacyanate 
• 75-15-0 carbon disulfide 
• 18469-52-8 methyl 4-(aminomethyl)benzoate 
• 874-60-2 4-methyl-benzoyl chloride 
• 463-71-8 thiophosgene 
• 6232-11-7 methyl 4-(aminomethyl)benzoate hydrochloride 
• 876-08-4 p-(chloromethyl)benzoyl chloride 

Downstream Products

• 35009-01-9 C₁₆H₁₇N₃O₂S 
• 37512-60-0 4-[(Aminothioxothioacetyl-amino)-methyl]-benzoic acid methyl ester 
• 37598-67-7 4-[(Aminothioxoacetyl-amino)-methyl]-benzoic acid methyl ester 
• 659741-14-7 methyl 4-(N'-(2-hydroxyethyl)thioureidomethyl)benzoate 
• 540737-38-0 methyl 4-(thioureidomethyl)benzoate 
• 37512-65-5 4-(4-imino-5,5-dimethyl-2-thioxo-oxazolidin-3-ylmethyl)-benzoic acid methyl ester 
• 37512-57-5 4-[(Cyanocarbothioyl-amino)-methyl]-benzoic acid methyl ester 
• 35008-99-2 C₂₀H₂₂N₄O₄S 

Relevant academic research and scientific papers

New mild and simple approach to isothiocyanates: A class of potent anticancer agents

In our current work, acetyl chloride-mediated synthesis of phenethyl isothiocyanate (PEITC) derivatives proves to be convenient and provides the expected products at good to excellent yields. Biological evaluation and structure-activity relationship analysis found that the novel compound 7 showed the best anticancer activity against human cancer cell line Panc1 and HGC27 compared with PEITC. Compounds 6 and 7 induced more apoptosis in pancreatic cancer cells but less toxicity in non-cancer cells. Further biological study demonstrated that 7 substantially increased intracellular reactive oxygen species (ROS) and depleted glutathione (GSH), leading to an oxidative stress to kill cancer cell.

Novel derivatives of benzimidazole and imidazo-pyridine and their use as medicaments

A compound of the formula wherein the substituents are as defined in the specification and pharmaceutical salts thereof having a good affinity for sub-types of melanocortin receptors making them useful for treating diseases in which such receptors are included such as pain, inflammatory conditions, etc.

Synthesis of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas and evaluation as modulators of the isoforms of nitric oxide synthase

Inhibition of the isoforms of nitric oxide synthase (NOS) has important applications in therapy of several diseases, including cancer. Using 1400W [N-(3-aminomethylbenzyl)acetamidine], thiocitrulline and N δ-(4,5-dihydrothiazol-2-yl)ornithine as lead compounds, series of N-benzyl- and N-phenyl-2-amino-4,5-dihydrothiazoles and thioureas were designed as inhibitors of NOS. Ring-substituted benzyl and phenyl isothiocyanates were synthesised by condensation of the corresponding amines with thiophosgene and addition of ammonia gave the corresponding thioureas in high yields. The substituted 2-amino-4,5-dihydrothiazoles were approached by two routes. Treatment of simple benzylamines with 2-methylthio-4,5-dihydrothiazole at 180 °C afforded the corresponding 2-benzylamino-4,5-dihydrothiazoles. For less nucleophilic amines and those carrying more thermally labile substituents, the 4,5-dihydrothiazoles were approached by acid-catalysed cyclisation of N-(2-hydroxyethyl)thioureas. This cyclisation was shown to proceed by an SN2-like process. Modest inhibitory activity was shown by most of the thioureas and 4,5-dihydrothiazoles, with N-(3-aminomethylphenyl)thiourea (IC50=13 μM vs rat neuronal NOS and IC50=23 μM vs rat inducible NOS) and 2-(3-aminomethylphenylamino)-4,5-dihydrothiazole (IC50=13 μM vs rat neuronal NOS and IC50=19 μM vs human inducible NOS) being the most potent. Several thioureas and 4,5-dihydrothiazoles were found to stimulate the activity of human inducible NOS in a time-dependent manner.